Axim Biotechnologies, Inc. (AXIM)

Sorry, no known transcripts

Recent filings

AXIM® Biotechnologies Issues Update Letter to Shareholders - Oct. 28, 2020

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19) - Oct. 6, 2020

AXIM® Biotechnologies Files Patent for Virus Binding Recombinant Protein for SARS-CoV-2 (COVID-19) and Begins Manufacturing - Sept. 30, 2020

AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 COVID-19 - Sept. 29, 2020

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1 - Sept. 22, 2020

AXIM® Biotechnologies Files Emergency Use Authorization With the FDA for First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies - Sept. 16, 2020

AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test - Aug. 24, 2020

Axim Biotechnologies, Inc. Just Filed Its Quarterly Report: Net Loss per Common ... - Aug. 18, 2020

Axim Biotechnologies: Applicable Only To Corporate Issuers - Aug. 14, 2020

Sapphire Biotech, Subsidiary of AXIM® Biotechnologies, Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute - Aug. 11, 2020

AXIM® Biotechnologies Applies for FDA Emergency Use Approval (EUA) for High Throughput, Patent-Pending Neutralizing Antibody Diagnostic Test for COVID-19 - Aug. 5, 2020

Departure of Directors or Certain - July 24, 2020

AXIM® Biotechnologies Unveils First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies and Files Pre-Emergency Use Authorization with the FDA - July 15, 2020

Axim Biotechnologies, Inc. Just Filed Its Quarterly Report: Net Loss per Common ... - July 2, 2020

Notification of inability to timely file Form 10-Q or 10-QSB - June 30, 2020

Axim Biotechnologies: Applicable Only To Corporate Issuers - June 30, 2020

Notice of Exempt Offering of Securities, item 06b - June 15, 2020

AXIM® Biotechnologies Appoints Dr. Alim Seit-Nebi as Chief Technology Officer of Subsidiary Sapphire Biotech - June 9, 2020

AXIM® Biotechnologies Begins Pre-Clinical Pharmacokinetic Animal Drug Studies on its Cancer Drug Compound SPX-1009 - June 1, 2020

Axim Biotechnologies: Index To Combined Financial Statements Independent Auditors’ Report - May 29, 2020

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Expands Research Division and Announces Dr. Sergei Svarovsky as Chief Scientific Officer of Subsidiary Sapphire Biotech - May 28, 2020

AXIM® Biotechnologies Expands Research Division and Announces Dr. Sergei Svarovsky as Chief Scientific Officer of Subsidiary Sapphire Biotech - May 27, 2020

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for Unique Early Detection Cancer Biomarker - May 21, 2020

Axim Biotechnologies, Inc. Just Filed Its Annual Report: Net Loss per Common ... - May 20, 2020

AXIM® Biotechnologies Files for Patent for Unique Biomarker for Early Detection of Cancer in Blood - May 18, 2020

As result of the global outbreak of the - May 14, 2020

Axim Biotechnologies: Documents Incorporated By Reference AXIM BIOTECHNOLOGIES, INC. FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2019 TABLE OF CONTENTS PART I - May 14, 2020

Axim Biotechnologies: Axim® Biotechnologies Issues Update Letter To Shareholders - May 13, 2020

AXIM® Biotechnologies Issues Update Letter to Shareholders - May 13, 2020

Entry into a Material Definitive - May 12, 2020

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files New U.S. Patent Application for Water-Soluble Cannabinoid Molecules - May 5, 2020

AXIM® Biotechnologies Files New U.S. Patent Application for Water-Soluble Cannabinoid Molecules - April 28, 2020

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Chewing Gum Comprising Cannabinoids and Nicotine - April 8, 2020

AXIM® Biotechnologies Receives New U.S. Patent Issuance for Chewing Gum Comprising Cannabinoids and Nicotine to Treat or Alleviate Tobacco Smoking - April 7, 2020

As result of the global outbreak of the - March 27, 2020

AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on New Compound Proving Tenfold Greater Inhibition of Tumor Metastasis Than Parent Compound - March 24, 2020

Axim Biotechnologies: Axim® Biotechnologies Completes Acquisition Of Oncology Research And Development Company Sapphire Biotech, Inc - March 19, 2020

AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc. - March 18, 2020

AXIM® Biotechnologies Nutraceutical Division Announces Launch of CBD-Based Gum for Professional and Amateur Golfers - Feb. 26, 2020

Axim® Biotechnologies Completes First Phase of Pharmacokinetic Clinical Study on Cannabinoid-Based Gum With Dronabinol - Feb. 18, 2020

AXIM® Biotechnologies Nutraceutical Division Announces Launch of Cannabinoid-Based Workout Gum and Other Upcoming Product Launches - Feb. 12, 2020

AXIM® Biotechnologies Acquiree Sapphire Biotech, Inc. Signs Sponsored Research Agreement with Arizona State University to Develop Metastatic Cancer Inhibitor - Feb. 10, 2020

AXIM® Biotechnologies Acquiree Sapphire Biotech, Inc. Signs License Agreement to Exclusively License Patent Rights in Cancer Technology - Jan. 22, 2020

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc. - Jan. 9, 2020

AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc. - Jan. 8, 2020

Axim Biotechnologies: Axim® Biotechnologies To Acquire Leading Oncology Research And Development Company Sapphire Biotech, Inc - Jan. 8, 2020

Axim Biotechnologies, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - Dec. 17, 2019

Entry into a Material Definitive - Dec. 17, 2019

Axim Biotechnologies, Inc. Just Filed Its Quarterly Report: Net Loss per Common ... - Nov. 14, 2019

AXIM® Biotechnologies Nutraceutical Division Announces Cannabinoid-Based Wellness Gum Product Line at Benzinga Cannabis Capital Conference - Oct. 22, 2019

AXIM® Biotechnologies Announces Cultivation Agreement to Establish Company’s First Domestic Industrial Hemp Source & Begins Harvesting - Sept. 17, 2019

Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical Studies - Sept. 12, 2019

Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol for Use in Upcoming Pre-Clinical Studies - Sept. 10, 2019

Axim Biotechnologies, Inc. Just Filed Its Quarterly Report: Net Loss per Common ... - Aug. 14, 2019

New U.S. Patent Allowance Granted To Axim® Biotechnologies For Anti-Microbial Compositions Comprising Cannabinoids - Aug. 8, 2019

AXIM® Biotechnologies Featured in Bloomberg Law for Robust Cannabinoid-Based Patent Portfolio - Aug. 6, 2019

AXIM® Biotechnologies Receives Seventh Private Label Gum Purchase Order Pushing Orders to Nearly $900,000 for Last Five Months - July 11, 2019

Axim Biotechnologies: Biotechnologies Signs Licensing Agreement With Leading Gum Distributor To Expand Nutraceutical Division - July 9, 2019

AXIM® Biotechnologies Signs Licensing Agreement With Leading Gum Distributor to Expand Nutraceutical Division - July 9, 2019

Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies, Inc.'s Cannabinoid Oral Care Products Registered For Use In Clinical Trials Through Australian Healthcare Partner - June 26, 2019

AXIM® Biotechnologies Signs Supply Agreement to Register Cannabinoid Oral Care Products in Clinical Trials for Gingivitis and Gum Disease - June 25, 2019

FOX Business Features Opinion Article Authored by AXIM Biotechnologies, Inc. CEO on Why Legal CBD is Good for Consumers and the Economy - June 5, 2019

AXIM® Biotechnologies Announces Additional Purchase Order for Nutraceutical Product With Leading Direct Selling Company - May 15, 2019

Axim Biotechnologies, Inc. Just Filed Its Quarterly Report: Net Loss per Common ... - May 15, 2019

Cannastocks2019 Live-Stream Investor Conference & Webinar May 15th - May 14, 2019

AXIM® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms - May 9, 2019

OTCQB Certification - May 7, 2019

Axim Biotechnologies: Biotechnologies, Inc. Nutraceutical Division Receives Purchase Order For 50,000 Boxes Of The Company’S Proprietary Cbd-Based Chewing Gum - April 23, 2019

AXIM® Biotechnologies, Inc. Nutraceutical Division Receives Purchase Order for 50,000 Boxes of the Company’s Proprietary CBD-Based Chewing Gum - April 23, 2019

AXIM® Biotechnologies, Inc. Announces Attendance and Presentation by Chief Technology Officer Lekhram Changoer at Kannaway® “Believe” National Convention - April 12, 2019

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Enters Services Agreement with CRO to Begin Clinical Studies on Dronabinol and CBD Chewing Gums - April 10, 2019

AXIM® Biotech Enters Services Agreement With CRO to Begin Clinical Studies On Dronabinol and CBD Chewing Gums - April 9, 2019

Axim Biotechnologies, Inc. Just Filed Its Annual Report: Net Loss per Common ... - April 8, 2019

AXIM® Biotechnologies, Inc. Appoints Mauricio Javier Gatto-Bellora to Company’s Board of Directors - April 4, 2019

Axim Biotechnologies: Biotechnologies, Inc. Appoints Mauricio Javier Gatto-Bellora To Company’S Board Of Directors - April 4, 2019

Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 - April 1, 2019

Medical Marijuana, Inc. Portfolio Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Topical Cream Containing Cannabinoids - March 27, 2019

Axim® Biotechnologies Receives New U.S. Patent Issuance for Topical Cream Containing Cannabinoids - March 19, 2019

Changes in Control of - Feb. 26, 2019

AXIM® Biotechnologies Announces Successful Microencapsulation of Cannabinoids Into Proprietary Chewing Gum Delivery Mechanism for Clinical Trials - Feb. 26, 2019

Medical Marijuana, Inc. Subsidiary Kannaway® Places Significant Initial Purchase Order for Major Investment Company AXIM® Biotechnologies CBD Chewing Gum - Feb. 14, 2019

New U.S. Patent Issuance Granted to AXIM® Biotechnologies for Oral Care Composition Containing Cannabinoids - Jan. 29, 2019

AXIM® Biotechnologies Launches New Website and Management Presentation To Outline Strategic Business Initiatives - Jan. 15, 2019

Axim Biotechnologies: Axim® Biotechnologies Launches New Website And Management PRESENTATION TO OUTLINE STRATEGIC BUSINESS INITIATIVES - Jan. 15, 2019

Axim Biotechnologies: Axim® Biotechnologies Appoints New Chief Executive Officer - Jan. 8, 2019

AXIM® Biotechnologies Appoints New Chief Executive Officer - Jan. 8, 2019

Entry into a Material Definitive - Dec. 7, 2018

New U.S. Patent Allowance Granted to AXIM® Biotechnologies for Suppository Formulations Comprised of Cannabinoids - Oct. 23, 2018

Axim® Biotechnologies Earns GMP License From Dutch Ministry of Health to Produce Cannabinoid-Based Pharmaceutical Products - Oct. 16, 2018

AXIM® Biotechnologies Signs LOI for Distribution of Products Throughout Australia and New Zealand - Sept. 13, 2018

Axim Biotechnologies: Biotechnologies Signs Loi For Distribution Of Products Throughout Australia And New Zealand - Sept. 13, 2018

AXIM® Biotechnologies Enters Canadian Market Through New Exclusive Distribution and License Agreement With Revive Therapeutics - Aug. 27, 2018

Axim Biotechnologies: Axim® Biotechnologies Enters Canadian Market Through New Exclusive DISTRIBUTION AND LICENSE AGREEMENT WITH REVIVE THERAPEUTICS - Aug. 27, 2018

Axim Biotechnologies, Inc. Just Filed Its Quarterly Report: Net Loss per Common ... - Aug. 17, 2018

AXIM® Biotechnologies to Present at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology - Aug. 15, 2018

Axim Biotechnologies: Applicable Only To Corporate Issuers - Aug. 14, 2018

Axim® Biotechnologies Announces Positive Results From Stability And Dissolution Tests On Medchew Rx Showing Greater Than 90% Availability - Aug. 7, 2018

AXIM® Biotechnologies to Present at 28th Annual International Cannabinoid Research Society Symposium in The Netherlands - June 28, 2018

Notice of Exempt Offering of Securities, item 06b - May 21, 2018

Axim Biotechnologies, Inc. Just Filed Its Quarterly Report: Net Loss per Common ... - May 18, 2018

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. IFP Advisors, Inc 50 N/A Sept. 30, 2019
2. IFP Advisors, Inc 50 N/A March 31, 2020
3. IFP Advisors, Inc 0 N/A June 30, 2020
4. IFP Advisors, Inc 0 N/A June 30, 2020
AXIM® Biotechnologies Issues Update Letter to Shareholders - Oct. 28, 2020

AXIM® Biotechnologies Files Patent for Virus Binding Recombinant Protein for SARS-CoV-2 (COVID-19) and Begins Manufacturing - Sept. 30, 2020

AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 COVID-19 - Sept. 29, 2020

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1 - Sept. 22, 2020

AXIM® Biotechnologies Files Emergency Use Authorization With the FDA for First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies - Sept. 16, 2020

AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test - Aug. 24, 2020

Sapphire Biotech, Subsidiary of AXIM® Biotechnologies, Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute - Aug. 11, 2020

AXIM® Biotechnologies Applies for FDA Emergency Use Approval (EUA) for High Throughput, Patent-Pending Neutralizing Antibody Diagnostic Test for COVID-19 - Aug. 5, 2020

AXIM® Biotechnologies Releases Rapid NeuCovix™ Test Results Showing Strong Agreement with COVID-19-Based Neutralization Tests - July 23, 2020

AXIM® Biotechnologies Welcomes Former Secretary of Veterans Affairs Peter O'Rourke to Company’s Board of Directors - July 21, 2020

AXIM® Biotechnologies Unveils First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies and Files Pre-Emergency Use Authorization with the FDA - July 15, 2020

 


Feedback